S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Axon Enterprise Stock Forecast, Price & News

-7.95 (-4.99%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
753,040 shs
Average Volume
626,479 shs
Market Capitalization
$10.37 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for Axon Enterprise and its competitors with MarketBeat's FREE daily newsletter.

Axon Enterprise logo

About Axon Enterprise

Axon Enterprise, Inc. engages in the development, manufacturing, and sale of conducted electrical weapons for personal defense. It operates through the TASER Weapons and Software and Sensors segments. The TASER Weapons segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.


Axon Updates One Key Risk Factor
November 23, 2021 |  nasdaq.com
Axon's Next Phase: Tasers for Everyone?
November 18, 2021 |  msn.com
Axon Enterprise (NASDAQ:AXON) Rating Reiterated by William Blair
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Ordnance & accessories, except vehicles & guided missiles
Systems Software
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$681 million
Cash Flow
$0.31 per share
Book Value
$16.27 per share


Net Income
$-1.72 million
Pretax Margin




Free Float
Market Cap
$10.37 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.37 out of 5 stars

Industrial Products Sector

98th out of 246 stocks

Ordnance & Accessories, Except Vehicles & Guided Missiles Industry

4th out of 8 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Axon Enterprise (NASDAQ:AXON) Frequently Asked Questions

Is Axon Enterprise a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Axon Enterprise stock.
View analyst ratings for Axon Enterprise
or view top-rated stocks.

When is Axon Enterprise's next earnings date?

Axon Enterprise is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Axon Enterprise

How were Axon Enterprise's earnings last quarter?

Axon Enterprise, Inc. (NASDAQ:AXON) announced its quarterly earnings results on Monday, November, 15th. The biotechnology company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $0.26 by $0.91. The biotechnology company earned $231.99 million during the quarter, compared to the consensus estimate of $201.11 million. Axon Enterprise had a negative trailing twelve-month return on equity of 2.26% and a negative net margin of 2.37%. The firm's quarterly revenue was up 39.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.01) EPS.
View Axon Enterprise's earnings history

What guidance has Axon Enterprise issued on next quarter's earnings?

Axon Enterprise updated its FY 2021 earnings guidance on Monday, November, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850 million-$850 million, compared to the consensus revenue estimate of $843.58 million.

What price target have analysts set for AXON?

8 brokerages have issued twelve-month price objectives for Axon Enterprise's shares. Their forecasts range from $170.00 to $250.00. On average, they anticipate Axon Enterprise's share price to reach $208.43 in the next year. This suggests a possible upside of 37.7% from the stock's current price.
View analysts' price targets for Axon Enterprise
or view top-rated stocks among Wall Street analysts.

Who are Axon Enterprise's key executives?

Axon Enterprise's management team includes the following people:

Who are some of Axon Enterprise's key competitors?

What other stocks do shareholders of Axon Enterprise own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

When did Axon Enterprise IPO?

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Axon Enterprise's stock symbol?

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Who are Axon Enterprise's major shareholders?

Axon Enterprise's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.57%), Baillie Gifford & Co. (6.91%), William Blair Investment Management LLC (2.86%), Morgan Stanley (2.70%), Lord Abbett & CO. LLC (2.11%) and Alliancebernstein L.P. (2.02%). Company insiders that own Axon Enterprise stock include Caitlin Elizabeth Kalinowski, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Matthew R Mcbrady, Matthew R Mcbrady and Patrick W Smith.
View institutional ownership trends for Axon Enterprise

Which major investors are selling Axon Enterprise stock?

AXON stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Janus Henderson Group PLC, TimesSquare Capital Management LLC, Invesco Ltd., NorthCoast Asset Management LLC, Morgan Stanley, William Blair Investment Management LLC, and UBS Group AG. Company insiders that have sold Axon Enterprise company stock in the last year include Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Matthew R Mcbrady, and Patrick W Smith.
View insider buying and selling activity for Axon Enterprise
or view top insider-selling stocks.

Which major investors are buying Axon Enterprise stock?

AXON stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Conestoga Capital Advisors LLC, Wellington Management Group LLP, Retirement Systems of Alabama, Franklin Resources Inc., Defender Capital LLC., New York State Teachers Retirement System, and Allianz Asset Management GmbH.
View insider buying and selling activity for Axon Enterprise
or or view top insider-buying stocks.

How do I buy shares of Axon Enterprise?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axon Enterprise's stock price today?

One share of AXON stock can currently be purchased for approximately $151.41.

How much money does Axon Enterprise make?

Axon Enterprise has a market capitalization of $10.37 billion and generates $681 million in revenue each year. The biotechnology company earns $-1.72 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Axon Enterprise have?

Axon Enterprise employs 2,548 workers across the globe.

What is Axon Enterprise's official website?

The official website for Axon Enterprise is www.axovant.com.

Where are Axon Enterprise's headquarters?

Axon Enterprise is headquartered at 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS.

How can I contact Axon Enterprise?

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at (480) 991-0797, via email at [email protected], or via fax at 480-991-0791.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.